Retrospective study of glycemic variability, BMI, and blood pressure in diabetes patients in the Digital Twin Precision Treatment Program.

The objective of this retrospective observational cohort study was to measure glycemic variability and reductions in body mass index (BMI), blood pressure (BP), and use of antihypertensive medications in type 2 diabetes (T2D) patients participating in the digital twin-enabled Twin Precision Treatment (TPT) Program. Study participants included 19 females and 45 males with T2D who chose to participate in the TPT Program and adhered to program protocols. Nine additional enrollees were excluded due to major program non-adherence. Enrollees were required to have adequate hepatic and renal function, no myocardial infarction, stroke, or angina ≤ 90 days before enrollment, and no history of ketoacidosis or major psychiatric disorders. The TPT program uses Digital Twin technology, machine learning algorithms, and precision nutrition to aid treatment of patients with T2D. Each study participant had ≥ 3 months of follow-up. Outcome measures included glucose percentage coefficient of variation (%CV), low blood glucose index (LBGI), high blood glucose index (HBGI), systolic and diastolic BP, number of antihypertensive medications, and BMI. Sixty-four patients participated in the program. Mean (± standard deviation) %CV, LBGI, and HBGI values were low (17.34 ± 4.35, 1.37 ± 1.37, and 2.13 ± 2.79, respectively) throughout the 90-day program. BMI decreased from 29.23 ± 5.83 at baseline to 27.43 ± 5.25 kg/m2. Systolic BP fell from 134.72 ± 17.73 to 124.58 ± 11.62 mm Hg. Diastolic BP decreased from 83.95 ± 10.20 to 80.33 ± 7.04 mm Hg. The percent of patients taking antihypertensive medications decreased from 35.9% at baseline to 4.7% at 90 days. During 90 days of the TPT Program, patients achieved low glycemic variability and significant reductions in BMI and BP. Antihypertensive medication use was eliminated in nearly all patients. Future research will focus on randomized case-control comparisons.

Vitamin D deficiency presenting like hypophosphatemic osteomalacia.

INTRODUCTION: Osteomalacia is one of the most common osteometabolic diseases. It is typically caused by lack of vitamin D and is characterized by mineralization deficiency of the osteoid matrix in the cortical and trabecular bone. Indians are at particularly high risk for developing osteomalacia, because of their traditional clothing style and skin color. This condition is frequently misdiagnosed and it can present with bone pain and muscle weakness. OBJECTIVE: We report a case of osteomalacia with predominant hypophosphatemia. CASE REPORT: A 41-year-old male presented with gradually progressive quadriparesis for past 6 months. Patient had low phosphorous (1.9 mg/dl) with calcium being 8.1 mg/dl and 25(OH)Vitamin D3 levels being 8.12 ng/ml. The patient was thought to have concomitant Vitamin D deficiency with possibility of tumor-induced osteomalacia. Further evaluation for the same was planned. However, patient was given a trial of Vitamin D supplementation before further investigations and had dramatic improvement in the form that muscle power improved gradually over next 6 weeks and was able to climb stairs after 2 months. Retrospectively patient gave a history of being at home for many months and there was no exposure to sunlight at all. The biochemical parameters normalized within 4 weeks of starting Vitamin D and serum alkaline phosphatase showed drastic reduction after 6 weeks. All his family members were screened and found to have Vitamin D deficiency including recent born twins having rachitic changes. This was a case of vitamin D deficiency, in 41-year-old male, which presented more like hypophosphatemic osteomalacia but characteristic history of lack of sunlight exposure and dramatic improvement with only vitamin D3 supplementation confirmed the diagnosis. CONCLUSION: The presentation of vitamin D deficiency can be varied and high index of suspicion is important for treatment of this common but frequently misdiagnosed condition.